Patents by Inventor Frank Follmann

Frank Follmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted S-alaninate derivatives
    Patent number: 11912692
    Abstract: The invention relates to substituted S-alaninate derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular vascular disorders, preferably thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications.
    Type: Grant
    Filed: August 11, 2023
    Date of Patent: February 27, 2024
    Assignee: Bayer Aktiengesellschaft
    Inventors: Hartmut Beck, Stefanie Mesch, Alexandros Vakalopoulos, Nils Pfaff, Stefanie Zimmermann, Markus Follmann, Elisabeth Kersten, Guillaume Levilain, Kartrin Partikel, Andreas Peter Broehl, Stefan Heitmeier, Julia Dietze-Torres, Lutz Lehmann, Kersten Matthias Gericke, Frank Süßmeier, Lars Bärfacker, Alexander Hillisch, Adrian Tersteegen, Anja Buchmüller, Christoph Gerdes
  • LIPOSOMAL COMPOSITION FOR PREVENTING OR EARLY TREATMENT OF PATHOGENIC INFECTION
    Publication number: 20230225972
    Abstract: The present invention relates to a liposomal composition for use as a medicament. In particular, the present invention relates to a liposomal composition for use in prevention or early treatment of pathogenic infection. More specifically, the liposomal composition is used for prevention, or early treatment, of pathogenic infection in the respiratory tract, preferably by nasal or pulmonary administration.
    Type: Application
    Filed: April 15, 2021
    Publication date: July 20, 2023
    Applicant: STATENS SERUM INSTITUT
    Inventors: Frank FOLLMANN, Peter ANDERSEN, Jes DIETRICH, Dennis CHRISTENSEN
  • Vaccines against Chlamydia sp.
    Publication number: 20210205433
    Abstract: The present invention describes an efficient vaccine against a Chlamydia trachomatis (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.
    Type: Application
    Filed: January 22, 2021
    Publication date: July 8, 2021
    Inventors: Frank Follmann, Ida Rosenkrands, Anja Olsen, Peter Andersen
  • Vaccines against sp
    Patent number: 10925954
    Abstract: The present invention describes an efficient vaccine against a Chlamydia trachomatis (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: February 23, 2021
    Assignee: Statens Serum Institut
    Inventors: Frank Follmann, Ida Rosenkrands, Anja Olsen, Peter Andersen
  • Vaccines against Chlamydia sp.
    Publication number: 20190099478
    Abstract: The present invention describes an efficient vaccine against a Chlamydia trachomatis (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.
    Type: Application
    Filed: April 18, 2018
    Publication date: April 4, 2019
    Inventors: Frank Follmann, Ida Kosenkrands, Anja Olsen, Peter Andersen
  • antigens for vaccine and diagnostic use
    Patent number: 8889142
    Abstract: The present invention is related to antigen from Chlamydia trachomatis which are recognized by specific antibodies from individuals infected with Chlamydia or which can induce T cells from the same individuals to secrete gamma-interferon. The T cell reactive antigens are present in a whole-cell lysate and have apparent molecular weights of 5-12, 16-20, 25-35 and 58-74 kDa as determined by SDS-PAGE. The antigens of the invention are believed to be useful in vaccines but also as diagnostic compositions.
    Type: Grant
    Filed: October 11, 2005
    Date of Patent: November 18, 2014
    Assignee: Statens Serum Institut
    Inventors: Michael Theisen, Anja Olsen, Robert Leah, Frank Follmann, Klaus Jensen, Peter Andersen
  • Vaccines against Chlamydia sp.
    Publication number: 20140275478
    Abstract: The present invention describes an efficient vaccine against a Chlamydia trachomatis (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.
    Type: Application
    Filed: March 17, 2014
    Publication date: September 18, 2014
    Applicant: Statens Serum Institut
    Inventors: Frank Follmann, Ida Rosenkrands, Anja Olsen, Peter Andersen
  • CHLAMYDIA TRACHOMATIS ANTIGENS FOR VACCINE AND DIAGNOSTIC USE
    Publication number: 20090304722
    Abstract: The present invention is related to antigens from Chlamydia trachomatis which are recognized by specific antibodies from individuals infected with Chlamydia or which can induce T cells from the same individuals to secrete gamma-interferon. The T cell reactive antigens are present in a whole-cell lysate and have apparent molecular weights of 5-12, 16-20, 25-35 and 58-74 kDa as determined by SDS-PAGE. The antigens of the invention are useful in vaccines but also as diagnostic compositions.
    Type: Application
    Filed: October 11, 2005
    Publication date: December 10, 2009
    Inventors: Michael Theisen, Anja Olsen, Robert Leah, Frank Follmann, Klaus Jensen, Peter Andersen